Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Spherix Incorporated (SPEX) -- an intellectual ... of intellectual property, today announced that the United States ... the Company in the month of August that are ... The issued patents are: ... issued August 19, 2014; and , U.S.RE45,095 issued ...
(Date:9/1/2014)... NEW YORK , Sept. 1, 2014 /PRNewswire/ ... report is available in its catalogue: ... Opportunities, 2019 http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html ... municipal corporations are the main governing bodies responsible ... management in cities. On an average, around 135,000 ...
(Date:8/31/2014)... , Aug. 31, 2014 Wockhardt Limited today ... program in Anti-Infective research when two of its drugs, ... Infectious Disease Product (QIDP) status from U.S. Food & ... which act against pathogens which have a high degree ... by Centre for Disease Control (a top U.S. government ...
(Date:8/31/2014)... August 31, 2014 This is ... state of the Epoxy Hardener industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
Breaking Biology Technology:United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3
... Biotech and pharma,companies are increasingly relying on ... Engineering & Biotechnology News (GEN). The,technique can provide ... drug,candidates for toxic effects, according to an article ... )., "Better screening technologies, noninvasive monitoring, and ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX:ONY) ... and preclinical studies of PX-866 were presented at ... Research (AACR) in,San Diego, held April 12-16, 2008. ... plans for these product candidates. Oncothyreon,is currently conducting ...
... Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced ... of Clinical Development as the,company prepares to enter ... the next 12 months., Dr. Goundis has ... of,clinical trials, including leadership positions at Speedel AG ...
Cached Biology Technology:Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays 2Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 2Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 3Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 4Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting 5Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 2Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 3Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 4
(Date:9/2/2014)... Air pollution regulations over the last decade in Taiyuan, ... there, accounting for a greater than 50% reduction in ... 2001 and 2010, according to researchers at the Columbia ... School of Public Health, the Shanxi Medical University, the ... and Shanghai Fudan University School of Public Health. , ...
(Date:9/2/2014)... Bavaria, the Tithonian Konservat-Lagersttte of lithographic limestone is ... of emblematic fossils from that area (for example, ... found fossil insects in the French equivalent of ... species representing the oldest known water treader. , ... Bavarian outcrops, fewer fossils have been obtained from ...
(Date:9/2/2014)... others are done in by it. New research at ... so-called stress gap in mice with very similar genetic ... better understand the development of psychiatric disorders such as ... unique experiences as it goes through its life. And ... expression of genes, and as a result, affect an ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... In April 2010, the US government adopted a new nuclear ... defense systems will reliably protect the continental United States in ... Bulletin of Atomic Scientists , published by SAGE, shows ... and would not be effective in real combat conditions. ...
... the human immune system,s assassin a protein called perforin ... funded by the Biotechnology and Biological Sciences Research Council (BBSRC) ... where they used powerful electron microscopes to study the mechanism ... research is published today (1800hrs, 31 October) in Nature ...
... have discovered a new member of a gene family that ... weight. The gene is the third member of the agouti ... One helps determine skin and hair color, and the other ... new gene, called agrp2, has been found exclusively in bony ...
Cached Biology News:US nuclear safety claim is a 'dangerous fantasy' 2US nuclear safety claim is a 'dangerous fantasy' 3Immune system assassin's tricks visualised for the first time 2Newly discovered gene enables fish to 'disappear' 2
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
... Solid phase reagent ... purification; Easy & unique ... Compatible with detergents and ... & recover non-envelop viruses ...
Biology Products: